Patent · US Active

Stable and soluble antibodies inhibiting TNFα

US8673310B2 · kind B2 · utility

9Cited by
46References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 25, 2009
Grant dateMar 18, 2014
Priority date
Expiry dateApr 4, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/94
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.